Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP/SLM HFA MDI in Japanese Pediatric Asthma
NCT02113436Phase 4Completed
- Sponsor
- GSK
- Start
- May 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of salmeterol in asthma (2 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in Total Asthma Symptom Score (Daytime Plus Night Time) at 8 weeks. Started May 2014; status: completed.
02
Drugs
salmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02113436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113436.